Albany Molecular Research, Inc.
http://www.amriglobal.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Albany Molecular Research, Inc.
Asia Deal Watch: Takeda To Team Up With Protagonist On Treatment For Polycythemia Vera
Plus alliances involving Formosa/Cristalia, Renalys/Travere, Astellas/Vivtex, Zydus/Synthon, AFT/Hyloris and Astellas/Mass General Brigham hospital.
Deal Watch: Ikena Cuts Staff After BMS Exits IO Partnership
Plus deals involving Lipocine/Verity, Vivtex/AI Proteins, Windtree/Lee’s Pharmaceutical, Biogen/Ji Xing, Sermonix/Henlius and news from the world of technology transfer.
Finance Watch: October Begins With A VC Mega-Round For Newly Named Iambic
Private Company Edition: Iambic, formerly known as Entos, closed a $100m series B venture capital round to advance its AI-discovered therapeutics. Also, Evozyne raised $81m and Acesion brought in €45m in series B rounds, while Mogrify added $10m to bring its series A to $46m.
Financing Quarterly Statistics, Q4 2022
During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Laboratory Testing Services
- Services
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Cedarburg Pharmaceuticals, Inc.
- Excelsyn Ltd.
- Hyaluron Inc.
- Gadea Pharmaceutical Group (Crystal Pharma)
- Prime European Therapeuticals S.p.A. (Euticals)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice